-
Biological & Pharmaceutical Bulletin 2017Orally disintegrating tablets (ODTs) are formulated to disintegrate upon contact with saliva, allowing administration without water. Olopatadine hydrochloride, a...
Orally disintegrating tablets (ODTs) are formulated to disintegrate upon contact with saliva, allowing administration without water. Olopatadine hydrochloride, a second-generation antihistamine, is widely used for treating allergic rhinitis. However, it has a bitter taste; therefore, the development of taste-masked olopatadine ODTs is essential. Some studies have suggested that citric acid could suppress the bitterness of drugs. However, these experiments were performed using solutions, and the taste-masking effect of citric acid on ODTs has not been evaluated using human gustatory sensation tests. Thus, this study evaluated citric acid's taste-masking effect on olopatadine ODTs. Six types of olopatadine ODTs containing 0-10% citric acid were prepared and subjected to gustatory sensation tests that were scored using the visual analog scale. The bitterness and overall palatability of olopatadine ODTs during disintegration in the mouth and after spitting out were evaluated in 11 healthy volunteers (age: 22.8±2.2 years). The hardness of the ODTs was >50 N. Disintegration time and dissolution did not differ among the different ODTs. The results of the gustatory sensation tests suggest that citric acid could suppress the bitterness of olopatadine ODTs in a dose-dependent manner. Olopatadine ODTs with a high content of citric acid (5-10%) showed poorer overall palatability than that of those without citric acid despite the bitterness suppression. ODTs containing 2.5% citric acid, yogurt flavoring, and aspartame were the most suitable formulations since they showed low bitterness and good overall palatability. Thus, citric acid is an effective bitterness-masking option for ODTs.
Topics: Administration, Oral; Citric Acid; Drug Compounding; Female; Flavoring Agents; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Olopatadine Hydrochloride; Solubility; Taste; Young Adult
PubMed: 28381800
DOI: 10.1248/bpb.b16-00828 -
Journal of Clinical and Diagnostic... Dec 2016The use of corticosteroids or antihistaminics in treatment of allergic rhinitis is known and practiced since long. The efficacy of topical use of fluticasone propionate...
INTRODUCTION
The use of corticosteroids or antihistaminics in treatment of allergic rhinitis is known and practiced since long. The efficacy of topical use of fluticasone propionate and Olopatadine Hydrochloride (HCL) for symptomatic relief of allergic rhinitis has been studied either individually or with other drugs. But very few studies show comparison between these two drugs.
AIM
To compare the efficacy of topical use of fluticasone propionate and olopatadine hydrochloride for symptomatic relief of allergic rhinitis.
DESIGN
In this single blind, randomized control study, the efficacy of topical use of olopatadine HCL was compared with fluticasone propionate for relieving symptoms of allergic rhinitis.
MATERIALS AND METHODS
The symptomatic cases were randomized in two groups for treatment using either olopatadine HCL or fluticasone propionate respectively. In each group, the Total Symptom Scores (TSS) and individual symptom scores were recorded before and after treatment with the help of symptom evaluation scale.
STATISTICAL ANALYSIS
Chi-square test, unpaired t-test, Mann Witney U-test, and Wilcoxon signed Rank test were used during analysis. The results of the comparison were noted and analysed.
RESULTS
During four week study period both TSS and individual symptom score were reduced (p<0.05) in either groups. The TSS decreased by an average of 85.07% for those treated with olopatadine and by 95.55% for those treated with fluticasone.
CONCLUSION
Overall fluticasone propionate was superior to olopatadine in relieving symptoms of allergic rhinitis (p<0.005).
PubMed: 28208892
DOI: 10.7860/JCDR/2016/20810.9120 -
CMAJ : Canadian Medical Association... Feb 2017
Topics: Adult; Azathioprine; Colitis, Ulcerative; Colonic Neoplasms; Contraindications; Early Detection of Cancer; Female; Humans; Immunosuppressive Agents; Influenza Vaccines; Influenza, Human; Olopatadine Hydrochloride; Practice Guidelines as Topic; Preventive Medicine; Skin Neoplasms; Uterine Cervical Neoplasms; Vaccines, Attenuated; Vaccines, Inactivated; Vaccines, Live, Unattenuated
PubMed: 28202558
DOI: 10.1503/cmaj.160640 -
Indian Journal of Dermatology,... 2017
Topics: Administration, Oral; Administration, Topical; Amino Acid Substitution; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Child; Collagen Type VII; Epidermolysis Bullosa Dystrophica; Glycine; Humans; Male; Olopatadine Hydrochloride; Protein Structure, Secondary; Treatment Outcome; Vitamin E
PubMed: 28164892
DOI: 10.4103/0378-6323.199426 -
International Forum of Allergy &... Apr 2017Allergic conjunctivitis (AC) is a disease of various agents that affects the physical and mental health of children. Although the most effective therapy has not been... (Randomized Controlled Trial)
Randomized Controlled Trial
Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study.
BACKGROUND
Allergic conjunctivitis (AC) is a disease of various agents that affects the physical and mental health of children. Although the most effective therapy has not been found so far, it is essential to explore the considerable therapeutic method. We compared the clinical efficacy of olopatadine, emedastine, loteprednol etabonate (LE), and vehicle for treating seasonal allergic conjunctivitis (SAC) in Chinese children.
METHODS
Eighty cases of 160 eyes aged from 5 to 10 years with SAC were available and those subjects were randomly distributed into 4 groups. Both their eyes received olopatadine hydrochloride 0.1% twice a day, emedastine difumarate 0.05% twice a day, or LE 0.5% 4 times a day, respectively, whereas those of the control group received artificial tears (AT) 0.5% 3 times a day. This study was conducted successfully and the observations were collected before treatment and on day 8 (±1 day) and day 15 (±2 days) afterward. The principal measurement of efficacy was focused on the signs and symptoms of the subjects, evaluated before and after treatment, in addition to visual acuity (VA) and fundus oculi.
RESULTS
On day 8 (±1 day) and day 15 (±2 days), all the antiallergic agents were found to be more effective than vehicle (p < 0.05) in terms of all the symptoms and signs. However, there was no statistical significance (p ≥ 0.05) shown among the treatment groups. There were no evident changes in VA and no clinically significant changes were observed in fundus oculi.
CONCLUSION
After the treatment, the efficacy presented a similar distribution among the trial groups.
Topics: Anti-Allergic Agents; Asian People; Benzimidazoles; Child; Child, Preschool; Conjunctivitis, Allergic; Female; Humans; Loteprednol Etabonate; Male; Olopatadine Hydrochloride; Single-Blind Method; Treatment Outcome
PubMed: 27869354
DOI: 10.1002/alr.21882 -
Pain Nov 2016Itch is a major indicator of psoriasis, but the underlying mechanisms behind this symptom are largely unknown. To investigate the neuronal mechanisms of psoriatic itch,...
Itch is a major indicator of psoriasis, but the underlying mechanisms behind this symptom are largely unknown. To investigate the neuronal mechanisms of psoriatic itch, we tested whether mice subjected to the imiquimod-induced psoriasis model exhibit itch-associated behaviors. Mice received daily topical applications of imiquimod to the rostral back skin for 7 days. Imiquimod-treated mice exhibited a significant increase in spontaneous scratching behavior directed to the treated area as well as touch-evoked scratching (alloknesis). To characterize this model, we measured the mRNA expression levels of pruritogens and itch-relevant receptors/channels using real-time reverse transcription PCR. The mRNA expression of MrgprA3, MrgprC11, and MrgprD decreased gradually over time in the dorsal root ganglion (DRG) cells. There was no significant change in the mRNA expression of TRPV1 or TRPA1 in DRG cells. TRPV4 mRNA expression was transiently increased in the DRG cells, whereas TRPM8 mRNA was significantly decreased. The mRNA expression levels of histidine decarboxylase and tryptophan hydroxylase 1, as well as the intensity of histamine and serotonin immunoreactivity, were transiently increased in the skin on day 2, returning to baseline by day 7. Histamine H1-receptor antagonists, chlorpheniramine and olopatadine, significantly inhibited spontaneous scratching on day 2, but not day 7. Neither chlorpheniramine nor olopatadine affected alloknesis on day 2 or day 7. These results may reflect the limited antipruritic effects of histamine H1-receptor antagonists on human psoriasis. The imiquimod-induced psoriasis model seems to be useful for the investigation of itch and its sensitization in psoriasis.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipruritics; Chlorpheniramine; Disease Models, Animal; Ganglia, Spinal; Gene Expression Regulation; Histidine Decarboxylase; Imiquimod; Male; Mice; Mice, Inbred C57BL; Olopatadine Hydrochloride; Pain Measurement; Pruritus; Random Allocation; Skin; TRPV Cation Channels; Tryptophan Hydroxylase
PubMed: 27437787
DOI: 10.1097/j.pain.0000000000000674 -
Case Reports in Gastroenterology 2016The clinical characteristic of gastrointestinal anisakiasis is severe abdominal pain after eating raw fish. Intestinal anisakiasis is more uncommon than gastric...
The clinical characteristic of gastrointestinal anisakiasis is severe abdominal pain after eating raw fish. Intestinal anisakiasis is more uncommon than gastric anisakiasis. Most patients with intestinal anisakiasis need hospitalization because anisakiasis can cause intestinal obstruction, ileus, peritonitis or intestinal perforation. We report a case of intestinal anisakiasis. A 43-year-old woman presented with symptoms of intermittent abdominal pain 2 days after eating raw fish. Her brother had eaten the same food and had been suffering from gastric anisakiasis. Abdominal ultrasonography in this patient showed localized jejunal wall thickening with dilated lumen of proximal jejunum and ascites. According to the clinical course and examinations, she was diagnosed with intestinal anisakiasis. Administration of prednisolone 5 mg/day and olopatadine hydrochloride 10 mg/day improved her symptoms quickly without hospitalization. Prednisolone was administered for 10 days, and olopatadine hydrochloride was administered for a total of 6 weeks according to ultrasonographic findings. Six months after the treatment, the abdominal ultrasonography demonstrated normal findings. This case demonstrates that ultrasonography was quite useful for the diagnosis and surveillance of intestinal anisakiasis. Furthermore, treatment with corticosteroid and an antiallergic agent could be an option for patients with intestinal anisakiasis.
PubMed: 27403099
DOI: 10.1159/000442971 -
Romanian Journal of Ophthalmology 2016To report the case of a 14-year-old male patient, with bilateral atopic keratoconjunctivitis with corneal ulcer. The patient complained of bilateral red, itchy eyes,...
To report the case of a 14-year-old male patient, with bilateral atopic keratoconjunctivitis with corneal ulcer. The patient complained of bilateral red, itchy eyes, decreased vision, photophobia, difficulty opening the eyelids upon awakening, palpebral edema, excessive tearing, along with yellowish mucous discharge. He had a two-year history of chronic blepharitis and recurrent episodes of conjunctivitis that were treated with Tobramycin and corticosteroid eye drops over the years. The patient's past medical history was significant for atopic dermatitis (AD) and he had a family history for atopy. At the eye exam: his best-corrected visual acuity at the initial presentation was 0.2 in the right eye and 1.0 in the left eye. The following elements were found upon the slit lamp biomicroscopy: Eyelids - +4 palpebral edema (pseudoptosis), Dennie-Morgan fold and Herthoge's sign were both present, tylosis; Conjunctiva - hyperaemia, cobblestone appearance of the tarsal papillae in both eyes, +2 chemosis; Cornea - corneal edema with a 8 mm × 4 mm epithelial defect in the inferior part of the cornea, covered partially by the lied, that stained positive with fluorescein dyes. Using the Evaluation Signs Severity for Allergic Ocular Diseases, a diagnosis of bilateral atopic keratoconjunctivitis with a grade 3 status for the right eye and a grade 2 status, was made. It was decided that he should be administered Olopatadine hydrochloride and Sodium cromoglicate eye drops, along with Moxifloxacin and steroid eye drops. The microbiological exam tested positive for staphylococcus aureus, and, based on the sensitivity pattern, Chloramphenicol eye drops had to be added to the treatment. After 2 weeks, his symptoms diminished, pain was significantly relieved and inflammation was markedly reduced, but the corneal ulcer persisted. In order to prevent corneal perforations, amniotic membrane transplantation (AMT) was used to promote epithelialization. A month later, the epithelial defect healed smoothly in an underlying vascular stromal scar and the visual acuity improved to 0.4 RE. This case demonstrated the role of patient history and close clinical obser-vation in the diagnosis of AKC. As this case showed, the use of topic medication along with amniotic membrane transplantation (AMT) was successful in the treatment of atopic keratoconjunctivitis and secondary staphylococcal aureus keratitis.
Topics: Administration, Ophthalmic; Adolescent; Anti-Allergic Agents; Anti-Asthmatic Agents; Anti-Bacterial Agents; Blepharitis; Conjunctivitis, Allergic; Corneal Ulcer; Cromolyn Sodium; Dermatitis, Atopic; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Glucocorticoids; Humans; Male; Moxifloxacin; Olopatadine Hydrochloride; Ophthalmic Solutions; Staphylococcal Infections; Staphylococcus aureus
PubMed: 29450349
DOI: No ID Found -
Clinical Ophthalmology (Auckland, N.Z.) 2015Symptom relief for the duration of 24 hours after treatment would benefit patients with allergic conjunctivitis.
BACKGROUND
Symptom relief for the duration of 24 hours after treatment would benefit patients with allergic conjunctivitis.
OBJECTIVE
To compare the safety and efficacy of olopatadine 0.77% with vehicle or olopatadine 0.2% in patients with allergic conjunctivitis in a conjunctival allergen-challenge clinical study.
PATIENTS AND METHODS
In this Phase III, multicenter, double-masked, parallel-group, randomized trial, patients with allergic conjunctivitis received olopatadine 0.77%, its vehicle, or olopatadine 0.2%, administered once at visits 3A (day 0), 4A (day 14 ±2), and 5 (day 21 +3). Allergic conjunctivitis-associated sign and symptom assessments included ocular itching, conjunctival redness, total redness, chemosis, and tearing scores. Adverse events and ocular safety parameters were also assessed.
RESULTS
A total of 202 qualifying patients were randomized. Olopatadine 0.77% was superior (P<0.001) to vehicle for treatment of ocular itching at 3, 5, and 7 minutes postchallenge at onset of action and 16- and 24-hour duration of action. Conjunctival redness mean scores were significantly lower for olopatadine 0.77% versus vehicle at all three post-conjunctival allergen-challenge time points: onset (-1.52 to -1.48; P<0.001), 16 hours (-1.50 to -1.38; P<0.01), and 24 hours (-1.58 to -1.38; P<0.05). At 24 hours, olopatadine 0.77% was superior to olopatadine 0.2% at all three postchallenge time points for ocular itching (P<0.05), conjunctival redness (P<0.05), and total redness (P<0.05). No clinically relevant differences in safety parameters or adverse events were observed between the treatment groups.
CONCLUSION
Olopatadine 0.77% is superior to both its vehicle and olopatadine 0.2% for the treatment of allergen-mediated ocular itching and conjunctival redness. Ocular itching symptom relief is maintained over 24 hours, supporting once-daily dosing and demonstrating a comparable safety profile to olopatadine 0.2%.
PubMed: 26392751
DOI: 10.2147/OPTH.S83263 -
Allergology International : Official... Apr 2015
Topics: CD4-Positive T-Lymphocytes; Cells, Cultured; Chemokine CCL17; Chemotaxis; Dermatitis, Atopic; Histamine Antagonists; Humans; Olopatadine Hydrochloride
PubMed: 25838101
DOI: 10.1016/j.alit.2014.10.008